Effects of Single Doses of Avagacestat (BMS-708163) on Cerebrospinal Fluid Aβ Levels in Healthy Young Men

An assessment of variability in CSF biomarkers in clinical experimental models: a meta-analysis

(2011) Jeffrey Waring et al.   Alzheimers & Dementia

Developing β-secretase inhibitors for treatment of Alzheimer’s disease

(2011) Arun K. Ghosh et al.   JOURNAL OF NEUROCHEMISTRY

Effect of concomitant administration of multiple doses of BMS-708163 on safety, tolerability, and the pharmacokinetics of midazolam, warfarin, caffeine, omeprazole, and dextromethorphan in healthy male subjects by administration of a modified Cooperstown cocktail

(2010) Randy Dockens et al.   Alzheimers & Dementia

A placebo-controlled, ascending, multiple-dose study to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of BMS-708163 in healthy young and elderly subjects

(2010) Jun-Sheng Wang et al.   Alzheimers & Dementia

A study to evaluate the effects of single oral doses of BMS-708163 in the cerebrospinal fluid of healthy young men

(2010) Gary Tong et al.   Alzheimers & Dementia

Development and validation of sensitive and selective LC–MS/MS methods for the determination of BMS-708163, a γ-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions

(2010) Huidong Gu et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor

(2010) Kevin W. Gillman et al.   ACS Medicinal Chemistry Letters

The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?

(2010) Kerensa Broersen et al.   Alzheimers Research & Therapy

A γ-secretase inhibitor decreases amyloid-β production in the central nervous system

(2009) Randall J. Bateman et al.   ANNALS OF NEUROLOGY

An update on treatment and prevention strategies for Alzheimer’s disease

(2009) Judith Neugroschl et al.   Current Neurology and Neuroscience Reports

Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease

(2009) David B Henley et al.   EXPERT OPINION ON PHARMACOTHERAPY

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

(2009) Niklas Mattsson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal

(2009) John Hardy   JOURNAL OF NEUROCHEMISTRY

How can we recognize “disease modification” effects?

(2009) E. R. Siemers   Journal of Nutrition Health & Aging

Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein  -Secretase for the Treatment of Alzheimer's Disease

(2009) R. L. Martone et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease

(2008) Adam S. Fleisher et al.   ARCHIVES OF NEUROLOGY

The Amyloid-β Rise and γ-Secretase Inhibitor Potency Depend on the Level of Substrate Expression

(2008) Catherine R. Burton et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

VBM anticipates the rate of progression of Alzheimer disease: A 3-year longitudinal study

(2008) S. Kinkingnehun et al.   NEUROLOGY